文献速递免疫规划

新型核苷酸包装疫苗将抗原和聚肌胞苷酸递送至树突状细胞并在体内产生强效抗体应答

Novel nucleotide-packaging vaccine delivers antigen and poly(I:C) to dendritic cells and generate a potent antibody response in vivo.
PubMed 文献 · Vaccine · 2024-03-27

研究开发了一种将抗原与沙眼衣原体Hc2蛋白DNA/RNA结合域融合的疫苗,可包装聚肌胞苷酸或双链DNA形成小颗粒,被巨噬细胞和树突状细胞摄取并强烈活化成熟;小鼠免疫后抗体应答强于未融合Hc2结合域的抗原与聚肌胞苷酸组合。

要点

  • 融合蛋白可包装聚肌胞苷酸或双链DNA形成小颗粒。
  • 颗粒被巨噬细胞和树突状细胞摄取并诱导强烈活化与成熟。
  • 小鼠免疫后抗体应答强于未融合Hc2结合域的抗原加聚肌胞苷酸组合。

核心结论

  • 融合蛋白包装聚肌胞苷酸后免疫小鼠诱导的抗体应答强于未融合Hc2 DNA/RNA结合域的抗原与聚肌胞苷酸组合。

研究设计与样本

  • 构建抗原与沙眼衣原体Hc2蛋白DNA/RNA结合域融合的融合蛋白疫苗,体外验证包装聚肌胞苷酸或双链DNA及细胞摄取活化,并进行小鼠免疫实验。

主要发现

  • 融合蛋白能将聚肌胞苷酸或双链DNA包装成小颗粒。
  • 这些小颗粒被巨噬细胞和树突状细胞摄取,并导致这些细胞强烈活化和成熟。
  • 小鼠免疫融合蛋白包装的聚肌胞苷酸后,抗体应答强于免疫未融合Hc2 DNA/RNA结合域的聚肌胞苷酸与抗原组合。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

An issue with many current vaccines is the dependency on broadly inflammatory adjuvants, such as aluminum hydroxide or aluminum salts that affect many immune- and non-immune cells. These adjuvants are not necessarily activating all antigen-presenting cells (APCs) that take up the antigen and most likely they also activate APCs with no antigen uptake, as well as many non-immune cells. Conjugation of antigen and adjuvant would enable the use of smaller amounts of adjuvant and avoid unnecessary tissue damage and activation of bystander cells. It would ensure that all APCs that take up the antigen would also become activated and avoid that immature and non-activated APCs present the antigen to T cells without a co-stimulatory signal, leading to tolerogenesis. We have developed a novel vaccine that co-deliver antigen and a nucleotide adjuvant to the same APC and lead to a strong activation response in dendritic cells and macrophages. The vaccine is constructed as a fusion-protein with an antigen fused to the DNA/RNA-binding domain from the Hc2 protein from Chlamydia trachomatis. We have found that the fusion protein is able to package polyinosinic:polycytidylic acid (poly(I:C)) or dsDNA into small particles. These particles were taken up by macrophages and dendritic cells and led to strong activation and maturation of these cells. Immunization of mice with the fusion protein packaged poly(I:C) led to a stronger antibody response compared to immunization with a combination of poly(I:C) and antigen without the Hc2 DNA/RNA-binding domain.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Bruun N, Laursen MF, Carmelo R, et al. Novel nucleotide-packaging vaccine delivers antigen and poly(I:C) to dendritic cells and generate a potent antibody response in vivo. Vaccine. 2024. PMID: 38538405. doi:10.1016/j.vaccine.2024.03.058

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。